Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA May Revise Import Notices; Bills Would Jeopardize Safety, Agency Says

Executive Summary

FDA is considering changes to its import warning notice procedures, the agency said in a July 25 letter to Commerce Committee Ranking Democrat Dingell (Mich.).
Advertisement

Related Content

Rx Re-Importation Bill Impact Could Be Limited By Canadian Export Laws
Rx Re-Importation Bill Impact Could Be Limited By Canadian Export Laws
Rx Re-Importation Bill Impact Could Be Limited By Canadian Export Laws
Senate Re-Importation Bill Opposed By Wholesalers, Chains; NCPA Supports
FDA Input On Coburn Drug Import Amendment Should Be Sought, Rep. Says
House Import Bill Shifts Burden To FDA; Rep. Dingell Opposes, Citing PDMA
House Import Bill Shifts Burden To FDA; Rep. Dingell Opposes, Citing PDMA
Advertisement
UsernamePublicRestriction

Register

PS036409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel